Letter: anti‐CTLA‐4‐associated colitis and inflammatory bowel disease pathogenesis – authors' reply

E-ISSN： 1365-2036|269-2813|8|1032-1033

ISSN： 0269-2813

Source： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.269-2813, Iss.8, 2015-10, pp. : 1032-1033

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Letter: anti‐CTLA‐4‐associated colitis and inflammatory bowel disease pathogenesis – authors' reply

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 8, 2015-10 ,pp. : 1032-1033

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: anti‐CTLA‐4‐associated colitis and inflammatory bowel disease pathogenesis

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 269-2813, Iss. 8, 2015-10 ,pp. : 1031-1032

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: anti‐CTLA‐4‐associated colitis and inflammatory bowel disease pathogenesis

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 8, 2015-10 ,pp. : 1031-1032

John Wiley & Sons Inc

Access to resources Recommend Favorite

Systematic review: colitis associated with anti‐CTLA‐4 therapy

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 4, 2015-08 ,pp. : 406-417

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: the safety of herpes zoster vaccination for patients with inflammatory bowel disease being treated with anti‐TNF medications—authors’ reply

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 3, 2018-02 ,pp. : 448-448

John Wiley & Sons Inc

Access to resources Recommend Favorite